Eversept Partners LP Purchases 10,475 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Eversept Partners LP raised its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 8.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 138,036 shares of the company’s stock after acquiring an additional 10,475 shares during the quarter. Eversept Partners LP owned approximately 0.19% of Structure Therapeutics worth $6,653,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the company. Capricorn Fund Managers Ltd bought a new stake in shares of Structure Therapeutics in the fourth quarter worth about $17,568,000. Principal Financial Group Inc. increased its holdings in Structure Therapeutics by 63.1% during the 4th quarter. Principal Financial Group Inc. now owns 1,284,210 shares of the company’s stock valued at $89,317,000 after purchasing an additional 496,726 shares during the period. SEB Asset Management AB bought a new position in Structure Therapeutics during the 1st quarter valued at approximately $11,811,000. Peregrine Capital Management LLC bought a new position in Structure Therapeutics during the 4th quarter valued at approximately $5,865,000. Finally, Siren L.L.C. lifted its holdings in Structure Therapeutics by 23.2% in the 1st quarter. Siren L.L.C. now owns 1,328,698 shares of the company’s stock worth $64,043,000 after buying an additional 250,000 shares during the period. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Analysts Set New Price Targets

GPCR has been the topic of a number of recent analyst reports. Wall Street Zen lowered Structure Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Canaccord Genuity Group started coverage on Structure Therapeutics in a report on Monday, April 27th. They set a “buy” rating and a $101.00 target price for the company. HC Wainwright dropped their price target on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, June 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $110.55.

Structure Therapeutics Price Performance

Shares of GPCR opened at $48.69 on Tuesday. Structure Therapeutics Inc. Sponsored ADR has a one year low of $15.80 and a one year high of $94.90. The company has a 50-day simple moving average of $45.67 and a two-hundred day simple moving average of $55.70. The firm has a market capitalization of $3.46 billion, a PE ratio of -55.96 and a beta of -1.50.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.04. Analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current fiscal year.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.